# Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus

> **NCT01742208** · PHASE2 · COMPLETED · sponsor: **Lexicon Pharmaceuticals** · enrollment: 36 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Sotagliflozin
- **DRUG:** Placebo
- **DRUG:** Sotagliflozin

## Key facts

- **NCT ID:** NCT01742208
- **Lead sponsor:** Lexicon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01742208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01742208, "Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01742208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*